Alamar Biosciences Launches Innovative NULISAseq Inflammation Panel AQ for Immune Response Profiling
Alamar Biosciences has made a significant step forward in the field of precision proteomics with the introduction of its groundbreaking NULISAseq™ Inflammation Panel AQ. This innovative tool is designed to revolutionize the quantitative assessment of immune responses in clinical studies by establishing new benchmarks in immune profiling.
Unveiled on January 22, 2025, in Fremont, California, the NULISAseq Inflammation Panel AQ provides researchers with a comprehensive platform for profiling over 150 key protein biomarkers in a single sample. With its exceptional sensitivity, this panel detects cytokine levels in both normal and pathological states, equipping scientists with the capability to monitor immune changes over time, especially before and after therapeutic interventions.
Yuling Luo, CEO and President of Alamar Biosciences, stated, "The NULISAseq Inflammation Panel AQ represents the largest panel available for absolute quantification. Its unparalleled sensitivity and dynamic range provide researchers with the tools to push the boundaries of immune system research, ultimately enhancing our understanding of health and disease."
The NULISAseq Inflammation Panel AQ leverages Alamar's proprietary NULISA™ technology, which combines a unique sequential immunocomplex capture and release mechanism with next-generation sequencing for high-sensitivity multiplexed protein analysis. This design minimizes sample requirements, needing only 25 μL of input, addressing challenges often faced in studies with limited samples. Consequently, it is also highly relevant for applications concerning oncology, autoimmune diseases, and infectious diseases.
For further information on the NULISAseq Inflammation Panel AQ, visit alamarbio.com/inflamAQ.
Alamar Biosciences is a private life sciences company dedicated to advancing precision proteomics for the early detection of diseases. The company’s patented NULISA™ platform, along with the ARGO™ HT system, integrates seamlessly with the latest genomic advancements to achieve an attomolar detection sensitivity, significantly surpassing the most sensitive protein detection technologies currently available. For additional details, please check alamarbio.com.
Unveiled on January 22, 2025, in Fremont, California, the NULISAseq Inflammation Panel AQ provides researchers with a comprehensive platform for profiling over 150 key protein biomarkers in a single sample. With its exceptional sensitivity, this panel detects cytokine levels in both normal and pathological states, equipping scientists with the capability to monitor immune changes over time, especially before and after therapeutic interventions.
Key Features and Benefits
- - Unmatched Sensitivity: The NULISAseq Inflammation Panel AQ boasts a remarkable quantification rate of over 99% in normal samples. This elevated sensitivity allows for the identification of subtle changes in immune responses, giving researchers a more detailed understanding of how immune functions are affected by various treatments.
- - Broad Dynamic Range: With a dynamic range spanning more than nine logs, this panel enables simultaneous quantification of both high and low abundance proteins from the same sample. This feature ensures a comprehensive data acquisition that can unveil critical insights in immune research.
- - High Reproducibility: The NULISAseq Inflammation Panel AQ achieves an average coefficient of variation (CV) of less than 10%. This reliability is crucial for studies involving large clinical cohorts, guaranteeing consistent and trustworthy results.
Yuling Luo, CEO and President of Alamar Biosciences, stated, "The NULISAseq Inflammation Panel AQ represents the largest panel available for absolute quantification. Its unparalleled sensitivity and dynamic range provide researchers with the tools to push the boundaries of immune system research, ultimately enhancing our understanding of health and disease."
The NULISAseq Inflammation Panel AQ leverages Alamar's proprietary NULISA™ technology, which combines a unique sequential immunocomplex capture and release mechanism with next-generation sequencing for high-sensitivity multiplexed protein analysis. This design minimizes sample requirements, needing only 25 μL of input, addressing challenges often faced in studies with limited samples. Consequently, it is also highly relevant for applications concerning oncology, autoimmune diseases, and infectious diseases.
For further information on the NULISAseq Inflammation Panel AQ, visit alamarbio.com/inflamAQ.
About Alamar Biosciences, Inc.
Alamar Biosciences is a private life sciences company dedicated to advancing precision proteomics for the early detection of diseases. The company’s patented NULISA™ platform, along with the ARGO™ HT system, integrates seamlessly with the latest genomic advancements to achieve an attomolar detection sensitivity, significantly surpassing the most sensitive protein detection technologies currently available. For additional details, please check alamarbio.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.